NCT Number: NCT04887935
Phase: PHASE1
Trial Summary: This is a study of the tolerability and safety of neoadjuvant dapagliflozin for patients with high-risk or very high risk prostatic adenocarcinoma prior to radical prostatectomy. The primary hypothesi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Washington University School of Medicine
Acronym:
Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives